Abstract

PIMAVANSERIN IN THE MANAGEMENT OF PSYCHOSIS IN PARKINSONIAN PATIENTS

Chaithanya T. K., Sam C. P.* and Sambathkumar R.

ABSTRACT

Parkinson’s disease psychosis or PDP is a condition that may develop in about 60 % of the Parkinson’s patients. Parkinson’s disease is often associated with hallucinations and psychosis. Atypical and typical antipsychotics were used to manage these symptoms. Recently US FDA has approved a new drug pimavanserin for the treatment of hallucination and delusion associated with parkinson’s disease psychosis. Pimavanserin is an NME (New Molecular Entity) that has not been approved elsewhere in the world for any other indication. It is the first anti-psychotic drug without dopamine blockade. With its highly targeted and selective receptor binding profile, pimavanserin provides a promising approach to the treatment of psychosis in parkinsonian patients, a condition which clearly lacks effective treatment options. However, it isnot approved for the treatment ofpatients with dementia related psychosisunrelated to hallucinations and delusionsassociated with Parkinson’s disease.

Keywords: Pimavanserin, psychosis, parkinsonism, hallucinations and delusions.